New AI Glucose Monitors Launch in India
What happened
Zydus Lifesciences launched new AI-powered continuous glucose monitors (CGMs) in India: Diasens™ and GlucoLive™. These enable real-time data streaming and integration with digital health apps, providing actionable visualizations of glucose trends. Patients and clinicians gain remote monitoring and AI analytics for early intervention.
Why it matters
Zydus' Diasens™ utilizes a reusable sensor, reducing the cost per test to a claimed ₹99, while GlucoLive™ offers a traditional single-use sensor model. Both CGMs sync glucose data every 5 minutes to a linked mobile app. The launch aligns with the Indian government's push to expand diabetes care access, where an estimated 8.8% of the population (over 77 million people) lives with diabetes. Zydus aims to capture a significant share of the growing glucose monitoring market, projected to reach \$450 million by 2025. Zydus anticipates that the AI-driven insights will enable more personalized treatment plans and improve patient adherence, potentially reducing long-term healthcare costs associated with diabetes complications. The company is partnering with healthcare providers and digital health platforms to integrate the CGMs into existing diabetes management programs.
Key numbers
- Zydus' Diasens™ utilizes a reusable sensor, reducing the cost per test to a claimed ₹99, while GlucoLive™ offers a traditional single-use sensor model.
- Both CGMs sync glucose data every 5 minutes to a linked mobile app.
- The launch aligns with the Indian government's push to expand diabetes care access, where an estimated 8.8% of the population (over 77 million people) lives with diabetes.
- Zydus aims to capture a significant share of the growing glucose monitoring market, projected to reach \$450 million by 2025.
What happens next
- The launch aligns with the Indian government's push to expand diabetes care access, where an estimated 8.8% of the population (over 77 million people) lives with diabetes.
- Zydus aims to capture a significant share of the growing glucose monitoring market, projected to reach \$450 million by 2025.
- Zydus anticipates that the AI-driven insights will enable more personalized treatment plans and improve patient adherence, potentially reducing long-term healthcare costs associated with diabetes complications.
Quick answers
What happened in New AI Glucose Monitors Launch in India?
Zydus Lifesciences launched new AI-powered continuous glucose monitors (CGMs) in India: Diasens™ and GlucoLive™. These enable real-time data streaming and integration with digital health apps, providing actionable visualizations of glucose trends. Patients and clinicians gain remote monitoring and AI analytics for early intervention.
Why does New AI Glucose Monitors Launch in India matter?
Zydus' Diasens™ utilizes a reusable sensor, reducing the cost per test to a claimed ₹99, while GlucoLive™ offers a traditional single-use sensor model. Both CGMs sync glucose data every 5 minutes to a linked mobile app. The launch aligns with the Indian government's push to expand diabetes care access, where an estimated 8.8% of the population (over 77 million people) lives with diabetes. Zydus aims to capture a significant share of the growing glucose monitoring market, projected to reach \$450 million by 2025. Zydus anticipates that the AI-driven insights will enable more personalized treatment plans and improve patient adherence, potentially reducing long-term healthcare costs associated with diabetes complications. The company is partnering with healthcare providers and digital health platforms to integrate the CGMs into existing diabetes management programs.
